Prognostic evaluation of comorbidities in patients with myelodysplastic syndrome / 中华血液学杂志
Chinese Journal of Hematology
;
(12): 196-201, 2015.
Article
in Chinese
| WPRIM
| ID: wpr-278878
ABSTRACT
<p><b>OBJECTIVE</b>To discuss the impact of comorbidities on the outcomes of patients with MDS.</p><p><b>METHODS</b>The clinical characteristics of 676 MDS patients with detailed comorbidities evaluations was analyzed retrospectively.</p><p><b>RESULTS</b>There were 395/676 cases (58.4%) with comorbidities (group 1), 281/676 cases (41.6%) without (group 2). Significant differences were seen in the distribution of age (≥ 60 y), bone marrow blasts, abnormal karyotype, WHO 2008 subtypes and IPSS-R risk cohorts (P<0.05) between the two groups. While gender, HGB concentrations, WBC levels, platelet levels and serum ferritin were not significantly different (P>0.05). Independent prognostic significance of comorbidities was seen in both uni-variate and multi-variate analyses (P<0.001). According to MDS-specific comorbidity index (MDS-CI), the median survival were 32(1-153) months, 19(2-85) months and 13(1-37) months in the low-risk, intermediate-risk and high-risk cohorts respectively, while 96(1-166) months in cohorts without any comorbidities, of which significant differences were seen (P<0.001). The MDS-CI allowed further stratification in the IPSS-R low-risk, intermediate-risk and high-risk cohorts (P<0.001).</p><p><b>CONCLUSION</b>Comorbidities provides prognostic stratification independently of IPSS-R for MDS patients.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prognosis
/
Blood Platelets
/
Myelodysplastic Syndromes
/
Comorbidity
/
Risk
/
Retrospective Studies
/
Abnormal Karyotype
/
Leukocytes
Type of study:
Etiology study
/
Observational study
/
Prognostic study
/
Risk factors
Limits:
Humans
Language:
Chinese
Journal:
Chinese Journal of Hematology
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS